Bleeding Risk Reduction in Relation to Predicted Factor IX Levels in Hemophilia B Patients Receiving Idelvion (rIX-FP)

被引：0
|
作者：
Roberts, John [1 ]
Fosser, Cecilia [2 ]
Tortorici, Michael [1 ]
Veldman, Alex [3 ]
Jacobs, Iris C. [4 ]
Sidhu, Jagdev [5 ]
机构：
[1] CSL Behring, King Of Prussia, PA USA
[2] Cytel, Cambridge, MA USA
[3] CSL Behring, Marburg, Germany
[4] CSL Behring, CRD, King Of Prussia, PA USA
[5] CSL, Parkville, Vic, Australia
来源：
BLOOD | 2016年 / 128卷 / 22期
关键词：
D O I：
10.1182/blood.V128.22.1411.1411
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1411
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Efficacy and Safety of Recombinant Fusion Protein Linking Coagulation Factor IX with Albumin (rIX-FP) in Previously Treated Patients with Hemophilia B Undergoing Major Orthopedic Surgeries
    Negrier, C.
    Lepatan, L. M. P.
    Karim, F. Abdul
    Lienhart, A.
    Lopez Fernandez, M. F.
    Pabinger, I.
    Mahlangu, J.
    Wolko, D.
    Voigt, C.
    Jacobs, I.
    Santagostino, E.
    HAEMOPHILIA, 2016, 22 : 63 - 63
  • [32] Efficacy, PK and Safety Results of Clinical Study Of Recombinant Fusion Protein Linking Coagulation Factor IX With Albumin (rIX-FP) In Previously Treated Patients With Hemophilia B
    Lubetsky, Aaron
    Lissitchkov, Toshko
    Santagostino, Elena
    Jotov, Gantcho
    Barazani-Brutman, Tami
    Voigt, Christine
    Moises, Tina
    Jacobs, Iris C.
    Martinowitz, Uri
    BLOOD, 2013, 122 (21)
  • [33] UPDATED POPULATION PHARMACOKINETIC ANALYSIS FOR NEW DOSING REGIMENS OF RECOMBINANT COAGULATION FACTOR IX ALBUMIN FUSION PROTEIN (RIX-FP) IN ADULT AND PEDIATRIC PATIENTS WITH HEMOPHILIA B.
    Zhang, Y.
    McKeand, W.
    Roberts, J.
    Goldstein, B.
    Tortorici, M.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S104 - S104
  • [34] Prophylactic dosing of rIX-FP maintains high observed and steady-state trough fix activity levels in patients with hemophilia B
    Castaman, G.
    Gill, J. C.
    Roberts, J.
    Jochems, J.
    Li, Y.
    Seifert, W.
    HAEMOPHILIA, 2018, 24 : 76 - 77
  • [35] Pharmacokinetic Results of Two Phase III Clinical Studies of Coagulation Factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in Previously Treated Patients with Hemophilia B (PROLONG-9FP)
    Santagostino, Elena
    Jacobs, Iris C.
    Voigt, Christine
    Feussner, Annettee
    Limsakun, Tharin
    BLOOD, 2014, 124 (21)
  • [36] Break-through bleeding in relation to predicted factor VIII levels in patients receiving prophylactic treatment for severe hemophilia A
    Collins, P. W.
    Blanchette, V. S.
    Fischer, K.
    Bjorkman, S.
    Oh, M.
    Fritsch, S.
    Schroth, P.
    Spotts, G.
    Astermark, J.
    Ewenstein, B.
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2009, 7 (03) : 413 - 420
  • [37] ORPHEE: A Real-World Study on rIX-FP Prophylaxis Use in Adolescent/Adult Patients With Hemophilia B
    Volot, Fabienne
    Castet, Sabine
    Fournel, Alexandra
    Frotscher, Birgit
    Gillet, Benjamin
    Desprez, Dominique
    Tardy, Brigitte
    Rauch, Antoine
    Chamouni, Pierre
    Biron-Andreani, Christine
    Valentin, Jean-Baptiste
    Harroche, Annie
    Dargaud, Yesim
    Petesch, Brigitte Pan
    d'Oiron, Roseline
    Berger, Claire
    Reynes, Claire
    Lauvray, Thomas
    de Raucourt, Emmanuelle
    Hassoun, Abel
    Lebreton, Aurelien
    Cussac, Vincent
    Catovic, Hasan
    Martin, Cedric
    Guillet, Benoit
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2025, 114 (03) : 508 - 516
  • [38] Safety and Efficacy of RIX-FP in Patients With Hemophilia B: Interim Results From A Phase IIIB Extension Study
    Santagostino, E.
    St Ledger, K.
    Veldman, A.
    Li, Y.
    Strelecki, M.
    Cole, G.
    Blackman, N.
    HAEMOPHILIA, 2017, 23 : 55 - 56
  • [39] Pharmacokinetic (PK) results of two Phase III clinical studies of coagulation factor IX (Recombinant) Albumin Fusion Protein (rIX-FP) in previous treated patients with hemophilia B (PROLONG-9FP)
    Santagostino, Elena
    Jacobs, Iris
    Voigt, Christine
    Feussner, Annette
    Limsakun, Tharin
    Easton, Rachael
    HAEMOPHILIA, 2014, 20 : 15 - 15
  • [40] Efficacy and safety results of a phase 3 pivotal clinical study of recombinant fusion protein linking coagulation factor IX with albumin (RIX-FP) in previously treated patients with hemophilia B
    Santagostino, E.
    Martinowitz, U.
    Lissitchkov, T.
    Pan-Petesch, B.
    Hanabusa, H.
    Oldenburg, J.
    Boggio, L.
    Negrier, C.
    Pabinger-Fasching, I
    Prondzinski, von Depka M.
    Altisent, C.
    Castaman, G.
    Yamamoto, K.
    Alvarez-Roman, M.
    Voigt, C.
    Jacobs, I
    JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2015, 13 : 228 - 228
12345